North America
Anixa Biosciences Nabs Option to Develop Cancer Vaccines With Verdi Solutions
If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.
Merck Buys Exclusive Rights to Develop Hengrui Pharma's Lp(a) Inhibitor Outside of China
Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.
Ontario Brain Institute, EpiSign Partner on Rare Genetic Disorder Diagnosis
OBI's Center for Analytics and EpiSign will refine and validate EpiSign's machine-learning algorithm that analyzes a person's epigenome to detect rare genetic disorders.
Elevation Oncology Terminates CLDN18.2-Targeted ADC, Reduces Workforce
The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
Everest Medicines Cleared by FDA to Study Cancer Vaccine in US Clinical Trials
The mRNA cancer vaccine, EVM14, induces an immune response to multiple tumor-associated antigens.